PCV5: MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE (PAD) PATIENTS: MODELLING THE RISK OF ISCHEMIC EVENTS AND THEIR ECONOMIC CONSEQUENCES  by Levy, E et al.
390 Abstracts
and side effects), and efficacy and safety of AA agents were
obtained from an expert panel of fifteen cardiologists. Unit
costs were estimated from published studies and Medicare
and state reimbursement rates. Expected costs for each
therapy were estimated for patients with and without struc-
tural heart disease (SHD), then weighted by corresponding
estimates of prescription frequencies to obtain expected
costs for a typical patient.
RESULTS: The annual costs of maintaining NSR in pa-
tients with and without SHD ranged from $3,763 (quini-
dine) to $4,749 (amiodarone) and from $2,912 (quinidine)
to $3,773 (sotalol) per patient, respectively. For a typical
patient, the total annual cost of maintaining NSR was
$3,809. Costs of therapy initiation and side effects were es-
timated to be $1,341 and $1,198, respectively; together,
these constituted 67% of total treatment cost. Costs of in-
patient care represented over 64% of total cost.
CONCLUSIONS: The cost of maintaining NSR with
available AA therapies is $3,809 for a typical AF/F patient.
Costs of inpatient therapy initiation and side effects consti-
tute the majority of the total cost. Total treatment costs are
highest for amiodarone and sotalol in patients with and
without SHD, respectively.
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OBJECTIVE: To determine drug costs to establish and
maintain treatment for hypertension with amlodipine and
felodipine.
METHODS: Data from published reports of 4 controlled
trials directly comparing amlodipine and felodipine were
analyzed. Three trials were identified from a comprehen-
sive Medline search; one trial was cited as a reference. For
one study, the unpublished study report supplemented in-
formation from the published report. In all 4 trials, sub-
jects with mild-to-moderate hypertension were started on
5 mg of study drug and titrated to higher dosages after 2
to 8 weeks if hypertension was not controlled. Maximum
dosages of amlodipine and felodipine were 10 mg in 3
studies. One study allowed titration to felodipine 20 mg.
In another study, lisinopril was added if hypertension was
not controlled by monotherapy. Data were pooled across
studies to determine the fraction of patients titrated to
greater than 5 mg or dual therapy. For the cost analysis,
average drug costs to establish and maintain treatment
were calculated from dosages during and at the end of
each trial, respectively. Where published reports did not
indicate timing of withdrawals, upper and lower limits
yielded high and low estimates of cost to establish treat-
ment. Average (US) wholesale prices were used for drug
costs. Statistical significance was assessed with a chi-
square test.
RESULTS: Fewer amlodipine (45%) than felodipine
(55%) patients were titrated to greater than 5 mg or dual
therapy (p  0.013). Average drug costs/patient-day
across the four studies ranged: 
Varying assumptions about timing of withdrawals
changed results by 3-percent or less. Higher costs with
felodipine were found in the study that allowed titration to
felodipine 20 mg.
CONCLUSION: The higher price of amlodipine may be
offset by higher dosages or greater need for dual therapy
with felodipine. Actual drug costs depend on dosages and
combinations used in practice.
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OBJECTIVES: The prevalence of PAD is known to be
underestimated as a large percentage of patients are not
diagnosed. As PAD is a risk marker of atherothrombotic
disease, potential ischemic events (ischemic stroke, myo-
cardial infarction) have to be taken into account while
studying the economic burden of PAD.
METHODS: A hypothetical cohort of 1000 patients with
established PAD was used for studying, on a 2-year fol-
low-up period basis, the average management of PAD pa-
tients with and without complications (amputations, is-
chemic stroke, myocardial infarction). Probabilities of
occurrence of ischemic events came from previous large
clinical trials and were used in a Markov model. The
costing was performed using French data costs.
RESULTS: The average cost of management of a PAD
patient over a two-year period was assessed taking into
account the probability of occurrence of complications
(amputation, ischemic stroke, myocardial infarction)
without any preventive treatment. This cost is almost 3
times higher than the average cost of management of a
PAD patient over a two-year period without any compli-
cations (4501 Euros compared to 1707 Euros).
CONCLUSION: The evaluation of the economic burden
of PAD has to take into account the risk of occurrence of
ischemic events. In these patients, a preventive treatment
with antiplatelet agents can significantly reduce the cost
Amlodipine Felodipine
Establish treatment $1.49–$1.59 $1.17–$1.71
Maintain treatment $1.63–$1.74 $1.28–$1.98
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of management by reducing the number of ischemic com-
plications.
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OBJECTIVES: Despite multiple pharmacological treatment
many patients with atrial fibrillation (Afib) are not com-
pletely “arrhythmia-free,” and remain at risk of chronic
complications such as stroke and cardiac morbidity. Cur-
rently, if first line treatment fails, most patients receive sec-
ond line pharmacological treatment. The emergence of new
technologies, aiming at “curing” the arrhythmia, e.g., com-
puter guided ablation techniques, has increased interest in
the economic aspects of current second line pharmacologi-
cal treatment of Afib. Therefore, we analyzed the average 5-
year costs of second-line pharmacological management of
paroxysmal and persistent Afib in France.
METHODS: The two most relevant current treatment
strategies were included: (1) rhythm control, i.e., com-
bined therapy with class Ic and III antiarrhythmics and (2)
rate control, i.e., digoxin therapy together with a beta-
blocker or a calcium antagonist. Both strategies are often
combined with either anticoagulation therapy or aspirin.
The analysis included probabilities of stroke, sudden death
and other cardiac or non-cardiac death, and direct medical
costs of drugs, follow-up and prevention or treatment of
complications from a health care insurance perspective
(discounted at 3% per annum). Clinical data were col-
lected from prospective randomized clinical trials, medical
resource use was obtained from expert opinion (two
round pure Delphi panel) from 10 centers, and unit costs
were obtained from official sources.
RESULTS: The average total 5-year cost of pharmaco-
logical management of Afib was FF108,500 per patient
(SD  66,300; MIN  26,500; MAX  335,000). Fol-
low-up visits and hospitalizations represented the largest
proportion of costs (39%), followed by the cost of treat-
ing congestive heart failure (CHF) (33%). Patients with
prevalent CHF at start cost on average FF149,000. Pa-
tients with persistent Afib cost on average FF40,000
more than patients with paroxysmal Afib.
CONCLUSIONS: Current second line pharmaceutical
management of Afib is expensive and provides opportu-
nities for new surgical or medical interventions.
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Telmisartan (Micardis®) is a new A-II inhibitor licensed
in the UK for the treatment of people with mild to mod-
erate hypertension. Randomised controlled trials (RCTs)
suggest that the clinical outcomes of treatment with telm-
isartan may compare favorably with other products in its
class as well as with products in other classes. Therefore
the purpose of this analysis is to evaluate the extent to
which the clinical benefits are translated into economic
benefits from the perspective of the UK NHS.
Data pertaining to key clinical outcomes (efficacy and ad-
verse events) are derived from RCTs comparing telmisar-
tan with several alternative medications. The ranges are
validated by a review of the clinical literature. The costs
of hypertension treatment and the management of ad-
verse events are derived from treatment algorithms and
published sources. The clinical and cost data are com-
bined in a decision-analytic model to perform four sets of
analyses:
1. Within-trial\3-month follow-up comparisons of hy-
pertension medication costs and outcomes
2. Beyond-trial\15-month follow-up comparisons of hy-
pertension medication costs and outcomes
3. Within-trial\3-month follow-up comparisons of hy-
pertension medication costs and adverse event treat-
ment costs and outcomes
4. Beyond-trial\15-month follow-up comparisons of hy-
pertension medication costs and adverse event treat-
ment costs and outcomes
The results are reported in both cost-effectiveness and
cost-consequences format and are evaluated for their sen-
sitivity to changes in key parameter values. The policy
implications and directions for future research are dis-
cussed.
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OBJECTIVES: To evaluate hospital utilization in patients
with atrial fibrillation or flutter (AF/F) using a managed
care claims database.
METHODS: A longitudinal integrated medical and phar-
macy claims database was used to identify patients who
received an AF/F diagnosis in the emergency room and/or
hospital in calendar year 1995. The earliest date for ei-
ther primary or secondary diagnosis of AF/F was desig-
nated as the index date for the purpose of analysis. Hos-
pital utilization both before and after the index date was
obtained for four AF/F patient cohorts: patients with no
history of congestive heart failure (CHF), myocardial inf-
arction (MI) or stroke as recorded within the last 12
